GPT and metabolic dysfunction-associated steatotic liver disease: On the other hand, a meta-analysis assessing the effects of 0.9–1.8 mg/day liraglutide on T2DM with NAFLD revealed favorable effects on both glycemic controls and metabolic abnormalities, including ALT [19].